// App-Quantinova.ai

109 : FGFR pathway genetic aberrations in cholangiocarcinoma: Demographics and experience with targeted therapy.

Researchers

Presenter

  • Apurva Jain

Principal Investigators

  • Rachna T. Shroff

  • Robin Kate Kelley

  • Ahmed Omar Kaseb

  • Ying Wang

  • Reham Abdel-Wahab

  • Daniel H. Ahn

  • Andrea Grace Bocobo

  • Funda Meric-Bernstam

  • Randi Isaacs

  • Tanios S. Bekaii-Saab

  • Milind M. Javle

Medical Centers

  • GI Medical Oncology Department, The University of Texas MD Anderson Cancer Center, Houston, TX

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • University of California, San Francisco, San Francisco, CA

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Clinical Oncology Department, Assiut University, Assiut, Egypt

  • The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital, Richard J. Solove Research Institute, Columbus, OH

  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • Department of Investigational Cancer Therapeutics (Phase 1 Program), Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Translational Clinical Oncology, NIBR, Novartis Pharmaceuticals Corporation, East Hanover, NJ

  • The Ohio State University Comprehensive Cancer Center, Columbus, OH

Locations

  • United States

  • Egypt

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Advanced biliary tract carcinoma

Biomarkers

  • Fibroblast growth factor receptor

Drug/Treatment

  • Methadone hydrochloride

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved